DLDina Liu

Dina Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dina Liu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Ailong Huang

    Department of Infectious Diseases Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education) Institute for Viral Hepatitis The Second Affiliated Hospital Chongqing Medical University Chongqing China

    1 shared publication
  • Chang Chen

    College of Pharmacy, Chongqing Medical University , Chongqing

    1 shared publication
  • Dan Nie

    Department of Gynecology, The Affiliated Hospital, Southwest Medical University, Luzhou, China

    1 shared publication
  • Fengli Xu

    Chengdu Second People's Hospital Chengdu Sichuan China

    1 shared publication
  • Huijun Liang

    Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education) Institute for Viral Hepatitis Department of Infectious Diseases The Second Affiliated Hospital Chongqing Medical University Chongqing 400010 China

    1 shared publication
  • Jiale Liu

    Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China; Institute of Stroke Research, Soochow University, Suzhou, Jiangsu Province, China

    1 shared publication

Latest Publications

  • Open Access

    HDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions

    by Jiaojiao Xie, Rui Liu, Ying Cai, Dina Liu

    Background: Many significant findings from recent studies have revealed the significance of histone deacetylase 1 (HDAC1) in the development of tumors and its strong association with tumor prognosis; these studies have mainly focused on one single cancer such as in lung cancer, breast cancer, and hepatocellular carcinoma (HCC). To date, there has been no comprehensive analysis and pan-analysis conducted from the overall perspective of cancer across all types. Hence, we analyzed public databases, conducted tube formation assay, and immunohistochemistry (IHC) staining of HDAC1 on six kinds of clinical samples to explore the prognostic and oncogenic effects of HDAC1 on 33 tumors for the first time. There currently remains a lack of efficient testing methods, therapies, and diagnostic and prognostic markers of tumor formation and development in different tumors. Methods: Our initial objective was to investigate the possible cancer-causing functions of HDAC1 in 33 different types of tumors by utilizing The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and many different online websites, such as Tumor IMmune Estimation Resource 2 (TIMER2), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Genotype Tissue Expression (GTEx) database, Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset, and University of ALabama at Brimingham CANcer data analysis portal (UALCAN) tool, and so on. We even used small interfering RNA (siRNA) to knock down HDAC2 in HCC cell lines. IHC of HDAC1 was performed. Results: HDAC1 exhibited high expression in numerous tumors, and strong correlations were observed between the messenger RNA (mRNA) levels of HDAC1 and the prognosis of individuals diagnosed with tumors. Human umbilical vein endothelial cells (HUVECs) tube formation and migration were significantly inhibited by conditioned media from HCC cells treated with siRNA of HDAC1. Several types of cancer have been found to exhibit elevated levels of phosphorylation at S421. Furthermore, as in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), and kidney renal papillary cell carcinoma (KIRP), HDAC1 expression was found to be correlated with inflammatory cell infiltration. Conclusions: The levels of HDAC1 are expected to adapt to clinical adjuvant targeted therapy in most types of solid cancer.


  • Open Access

    Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid

    by Kang Wu, Yi Liu, Jie Xia, Jiale Liu, Kai Wang, Huijun Liang, Fengli Xu, Dina Liu, Dan Nie, Xin Tang, et al.

    Although the dysregulation of bile acid (BA) composition has been associated with fibrosis progression, its precise roles in liver fibrosis is poorly understood. This study demonstrates that solute carrier family 27 member 5 (SLC27A5), an enzyme involved in BAs metabolism, is substantially downregulated in the liver tissues of patients with cirrhosis and fibrosis mouse models. The downregulation of SLC27A5 depends on RUNX family transcription factor 2 (RUNX2), which serves as a transcriptional repressor. The findings reveal that experimental SLC27A5 knockout (Slc27a5−/−) mice display spontaneous liver fibrosis after 24 months. The loss of SLC27A5 aggravates liver fibrosis induced by carbon tetrachloride (CCI4) and thioacetamide (TAA). Mechanistically, SLC27A5 deficiency results in the accumulation of unconjugated BA, particularly cholic acid (CA), in the liver. This accumulation leads to the activation of hepatic stellate cells (HSCs) by upregulated expression of early growth response protein 3 (EGR3). The re‐expression of hepatic SLC27A5 by an adeno‐associated virus or the reduction of CA levels in the liver using A4250, an apical sodium‐dependent bile acid transporter (ASBT) inhibitor, ameliorates liver fibrosis in Slc27a5−/− mice. In conclusion, SLC27A5 deficiency in mice drives hepatic fibrosis through CA‐induced activation of HSCs, highlighting its significant implications for liver fibrosis treatment.